Imetelstat (Rytelo): a promising treatment for adults with lower-risk MDS and transfusion-dependent anemia.
作者信息
Ahmed Iqra Furqan, Tahseen Ayman, Fakhoury Marc, Shaik Muzzamil Hussain, Gandhi Fenil, Belletieri Christopher
机构信息
Department of Internal Medicine, Liaquat National Hospital and Medical College Karachi, Pakistan.
Department of Internal Medicine, Karachi Medical and Dental College, Karachi, Pakistan.
出版信息
Ann Med Surg (Lond). 2024 Oct 28;86(12):6918-6920. doi: 10.1097/MS9.0000000000002698. eCollection 2024 Dec.
Abstract
摘要
相似文献
1
Imetelstat (Rytelo): a promising treatment for adults with lower-risk MDS and transfusion-dependent anemia.艾美司他（Rytelo）：一种治疗低危骨髓增生异常综合征（MDS）和输血依赖型贫血成人患者的有前景的疗法。
Ann Med Surg (Lond). 2024 Oct 28;86(12):6918-6920. doi: 10.1097/MS9.0000000000002698. eCollection 2024 Dec.
2
Imetelstat: First Approval.依美替萨：美国获批。
Drugs. 2024 Sep;84(9):1149-1155. doi: 10.1007/s40265-024-02080-x. Epub 2024 Aug 20.
3
Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS.艾美司他：低危骨髓增生异常综合征治疗领域的新成员。
Blood. 2025 Jan 30;145(5):469-474. doi: 10.1182/blood.2024025702.
4
Examining the safety and efficacy of imetelstat in low-risk myelodysplastic syndrome.研究艾美替尼在低危骨髓增生异常综合征中的安全性和有效性。
Expert Opin Pharmacother. 2025 Apr;26(5):525-533. doi: 10.1080/14656566.2025.2471518. Epub 2025 Feb 27.
5
6
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.在一项 II 期研究中，imetelstat 可使低危骨髓增生异常综合征高输血负担患者实现有意义且持久的输血独立性。
J Clin Oncol. 2021 Jan 1;39(1):48-56. doi: 10.1200/JCO.20.01895. Epub 2020 Oct 27.
7
Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.依特司他，一种新型的首创端粒酶抑制剂：作用机制、临床和转化科学。
Clin Transl Sci. 2024 Nov;17(11):e70076. doi: 10.1111/cts.70076.
8
Imetelstat: Finally a disease-modifying treatment for lower-risk myelodysplastic syndromes?依特司他：低危骨髓增生异常综合征的首款靶向药物？
Med. 2024 Mar 8;5(3):184-186. doi: 10.1016/j.medj.2024.01.004.
9
Imetelstat (Rytelo) for myelodysplastic syndromes.用于骨髓增生异常综合征的艾美司他（Rytelo）
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e169-e170. doi: 10.58347/tml.2024.1712d.
10
Imetelstat in myeloid malignancies: current data and future directions.艾美司他在髓系恶性肿瘤中的应用：当前数据与未来方向。
Expert Rev Anticancer Ther. 2025 May;25(5):517-528. doi: 10.1080/14737140.2025.2482721. Epub 2025 Mar 28.
本文引用的文献
1
Investigation of NK cell function against two target hematological cell line using radioactive chromium assay.使用放射性铬测定法研究自然杀伤细胞对两种靶血液学细胞系的功能。
Appl Radiat Isot. 2024 Apr;206:111251. doi: 10.1016/j.apradiso.2024.111251. Epub 2024 Feb 24.
2
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.Imetelstat用于复发或对促红细胞生成素刺激剂难治的低危骨髓增生异常综合征患者（IMerge）：一项多中心、随机、双盲、安慰剂对照的3期试验。
Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1.
3
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.骨髓增生异常综合征：2023 年关于诊断、风险分层和治疗的更新。
Am J Hematol. 2023 Aug;98(8):1307-1325. doi: 10.1002/ajh.26984. Epub 2023 Jun 8.
4
New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat.用于治疗伴有环形铁粒幼细胞的髓系肿瘤的新药：罗特西普与艾美司他。
Am J Hematol. 2021 Jul 1;96(7):761-763. doi: 10.1002/ajh.26197. Epub 2021 May 3.
5
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.在一项 II 期研究中，imetelstat 可使低危骨髓增生异常综合征高输血负担患者实现有意义且持久的输血独立性。
J Clin Oncol. 2021 Jan 1;39(1):48-56. doi: 10.1200/JCO.20.01895. Epub 2020 Oct 27.
6
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.低风险骨髓增生异常综合征的早期治疗起始可产生更早且更高的输血独立性发生率。
Leuk Res. 2017 Sep;60:123-128. doi: 10.1016/j.leukres.2017.07.008. Epub 2017 Aug 1.
7
Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome.
Leuk Res. 2007 Aug;31(8):1097-1105. doi: 10.1016/j.leukres.2007.01.012. Epub 2007 Mar 12.
Zotero 插件